Explore the words cloud of the BRCA-ERC project. It provides you a very rough idea of what is the project "BRCA-ERC" about.
The following table provides information about the project.
Coordinator |
UNIVERSITY COLLEGE LONDON
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 2˙497˙841 € |
EC max contribution | 2˙497˙841 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2016-ADG |
Funding Scheme | ERC-ADG |
Starting year | 2017 |
Duration (year-month-day) | from 2017-09-01 to 2022-08-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITY COLLEGE LONDON | UK (LONDON) | coordinator | 2˙264˙589.00 |
2 | UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST | UK (LONDON) | participant | 233˙251.00 |
Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRCA-ERC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRCA-ERC" are provided by the European Opendata Portal: CORDIS opendata.
A need for speed: mechanisms to coordinate protein synthesis and folding in metazoans
Read MoreJust because we can, should we? An anthropological perspective on the initiation of technology dependence to sustain a child’s life
Read MoreUnderstanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell
Read More